Vir Biotechnology Ownership
| VIR Stock | USD 6.95 0.21 3.12% |
Shares in Circulation | First Issued 2018-06-30 | Previous Quarter 136.2 M | Current Value 136.7 M | Avarage Shares Outstanding 122.9 M | Quarterly Volatility 15.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Vir |
Vir Stock Ownership Analysis
About 74.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.75. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vir Biotechnology has Price/Earnings To Growth (PEG) ratio of 1.14. The entity recorded a loss per share of 3.93. The firm had not issued any dividends in recent years. Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California. Vir Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 444 people. For more information please call George Scangos at 415 906 4324 or visit https://www.vir.bio.Vir Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vir Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vir Biotechnology backward and forwards among themselves. Vir Biotechnology's institutional investor refers to the entity that pools money to purchase Vir Biotechnology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Voloridge Investment Management, Llc | 2024-06-30 | 1.2 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.2 M | Renaissance Technologies Corp | 2024-09-30 | 1.2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.1 M | D. E. Shaw & Co Lp | 2024-06-30 | 922.6 K | Northern Trust Corp | 2024-09-30 | 878.9 K | Bank Of America Corp | 2024-06-30 | 851.8 K | Bank Of New York Mellon Corp | 2024-06-30 | 813.3 K | Bridgeway Capital Management, Llc | 2024-06-30 | 788.7 K | Sb Investment Advisers (uk) Ltd | 2024-09-30 | 16.7 M | Blackrock Inc | 2024-06-30 | 16.4 M |
Vir Biotechnology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vir Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vir Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vir Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vir Biotechnology Outstanding Bonds
Vir Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vir Biotechnology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vir bonds can be classified according to their maturity, which is the date when Vir Biotechnology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| Virgin Media Communications Corp BondUS92769VAJ89 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Viper Energy Partners Corp BondUS92763MAA36 | View | |
| Virgin Media 55 Corp BondUS92769XAP06 | View | |
| Virgin Media Investment Corp BondUS92769XAR61 | View |
Vir Biotechnology Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 4th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 18th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
Pair Trading with Vir Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vir Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vir Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving against Vir Stock
The ability to find closely correlated positions to Vir Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vir Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vir Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vir Biotechnology to buy it.
The correlation of Vir Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vir Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vir Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vir Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.